Literature DB >> 7633653

Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies--comparative studies on frozen and paraffin sections.

W Remmele1, V Mühlfait, H G Keul.   

Abstract

The estimation of the Ki-67 index in human breast cancer tissue has been proven to be a useful prognostic tool. The examination can be performed, however, only on frozen sections (FS). The development of an antibody directed against parts of the Ki-67 antigen (MIB-1) has opened a new route to determine the proliferative activity on paraffin sections (PS). MIB-1 immunohistochemistry is used instead of Ki-67 immunohistochemistry if a tumour is delivered to the pathologist after formalin fixation or if that part of the tissue suspicious for breast cancer must be totally embedded in order to confirm the diagnosis. The present study compares the findings of Ki-67 (FS) and MIB-1 (FS and PS) immunohistochemistry in a total of 544 cases of human breast cancer. The findings confirm a good statistical correlation between the Ki-67 and the MIB-1 findings. The MIB-1 results are 2-2.5 times higher in FS than in PS. Good agreement exists between the Ki-67 indices determined on FS and the MIB-1 indices determined on PS. If the cut-off value for the separation of Ki-67 negative and positive cases is defined as 10%-20%, a MIB-1 index in PS of 10% permits the correct prediction of a negative Ki-67 index in 97% of the cases, and a MIB-1 index of 30% or more correctly predicts a positive Ki-67 index in 90% or more of the cases. Hence, the determination of the MIB-1 index on PS may replace the determination of the Ki-67 index on FS with a high degree of probability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633653     DOI: 10.1007/bf00193164

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  11 in total

1.  Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues.

Authors:  J Gerdes; M H Becker; G Key; G Cattoretti
Journal:  J Pathol       Date:  1992-09       Impact factor: 7.996

2.  Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.

Authors:  A A Sahin; J Ro; J Y Ro; M B Blick; A K el-Naggar; N G Ordonez; H A Fritsche; T L Smith; G N Hortobagyi; A G Ayala
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

3.  Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10.

Authors:  D M Schonk; H J Kuijpers; E van Drunen; C H van Dalen; A H Geurts van Kessel; R Verheijen; F C Ramaekers
Journal:  Hum Genet       Date:  1989-10       Impact factor: 4.132

4.  Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells.

Authors:  J H van Dierendonck; R Keijzer; C J van de Velde; C J Cornelisse
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

5.  Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1.

Authors:  D McCormick; H Chong; C Hobbs; C Datta; P A Hall
Journal:  Histopathology       Date:  1993-04       Impact factor: 5.087

6.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

7.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

8.  Ki-67 immunostaining in human breast tumors and its relationship to prognosis.

Authors:  H O Wintzer; I Zipfel; J Schulte-Mönting; U Hellerich; S von Kleist
Journal:  Cancer       Date:  1991-01-15       Impact factor: 6.860

9.  Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies.

Authors:  J Gerdes; H Pickartz; J Brotherton; J Hammerstein; H Weitzel; H Stein
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

10.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

View more
  3 in total

1.  PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations.

Authors:  Ying Jiang; Lin Zou; Chunhui Zhang; Song He; Chun Cheng; Junfei Xu; Weiqi Lu; Yong Zhang; Hua Zhang; Donglin Wang; Aiguo Shen
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-03       Impact factor: 4.553

2.  The expression and prognosis of Emi1 and Skp2 in breast carcinoma: associated with PI3K/Akt pathway and cell proliferation.

Authors:  Xiaobing Liu; Hua Wang; Jing Ma; Junfei Xu; Chenyi Sheng; Shuyun Yang; Lingling Sun; Qichao Ni
Journal:  Med Oncol       Date:  2013-10-25       Impact factor: 3.064

3.  MIB-1 labelling index is an independent prognostic marker in primary breast cancer.

Authors:  R L Jansen; P S Hupperets; J W Arends; S R Joosten-Achjanie; A Volovics; H C Schouten; H F Hillen
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.